Browse the evidence

The latest randomized clinical trial on pramlintide/metreleptin was stopped due to safety concerns.

Practitioners should be cautious about the use of pramlintide/metreleptin until safety concerns are addressed.

Preoperative use of GLP-1 receptor agonists is not significantly associated with the odds of postoperative aspiration pneumonia.

Clinicians may reconsider the necessity of withholding GLP-1 RAs preoperatively based on these findings.

Patients using GLP-1 receptor agonists are more likely to be female and diagnosed with both obesity and diabetes compared to nonusers.

Understanding the demographics of GLP-1 RA users can inform targeted interventions and education.

Trials with both smartphone and in-person components exhibited the highest racial minority enrollment.

Combining technology with in-person interactions may further improve minority enrollment in weight loss trials.

Many racial and ethnic minority groups are under-represented in clinical trials of behavioral weight loss treatment.

Recognizing the under-representation of minorities can guide efforts to improve enrollment in clinical trials.

The results of the analysis should be interpreted with caution due to the minority representation of BPD and mini-GBP among bariatric surgeries.

Practitioners should be aware of the limitations in the data when recommending surgical options.

Further research with larger sample sizes is needed to confirm these results.

Practitioners should be aware that current findings are preliminary and require further validation.

The number of people living with obesity has tripled worldwide since 1975.

Public health initiatives should address the rising obesity rates.

Only a small percentage of the studies reviewed used mobile platforms for interventions.

Future interventions may benefit from increased use of mobile technology.

There are few data that convincingly demonstrate significant reductions in risk of gastrointestinal cancers following weight-reducing strategies.

Practitioners should be cautious in expecting significant cancer risk reductions from weight loss interventions.

No dietary intervention was introduced during the experimental period.

The findings are solely attributed to the exercise intervention, emphasizing its effectiveness without dietary influence.

Higher sustained pharmacy costs were the main driver of the cost difference favoring MBS over GLP-1 receptor agonists.

Healthcare providers should consider ongoing medication costs when recommending obesity treatments.

Current methodologies for measurements of vascular markers need to be further standardized.

Practitioners should be aware of the variability in vascular marker measurements and the need for standardization.

Restrictive diets such as very-low-carb, ketogenic, very-low-calorie diets, and intermittent fasting have scarce evidence for direct benefit to NAFLD.

Practitioners should be cautious in recommending restrictive diets for NAFLD due to insufficient evidence of their benefits.

The random forest classification algorithm exhibits superior accuracy rates of 97% for Obesity_Type_I, 99% for Obesity_Type_II, and 83% for Obesity_Type_III compared to alternative classifiers.

Practitioners can utilize machine learning algorithms, particularly random forests, for more accurate obesity classification.

The study demonstrates the efficacy of machine learning methodologies in forecasting different forms of obesity.

Machine learning can be a powerful tool for predicting obesity, aiding in prevention and management strategies.

Maintaining or losing weight after becoming overweight or obese does not reduce the risk of coronary heart disease (CHD) or death.

Weight management strategies may not be effective for reducing CHD or mortality risk in this demographic.

There is no protective effect of weight loss on mortality risk.

Weight loss may not contribute to longevity in this population.

Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.

Clinicians may consider semaglutide as the preferred option over tirzepatide for this patient population.

The number of adults with diabetes globally increased from 108 million in 1980 to 422 million in 2014.

Healthcare practitioners should be aware of the significant increase in diabetes prevalence when planning interventions.

Worldwide age-standardized adult diabetes prevalence doubled from 4.3% to 9.0% in men and from 5.0% to 7.9% in women.

This information is crucial for public health initiatives targeting diabetes prevention and management.

Few companies in the US reduced portion sizes of ultra-processed foods since 2002.

Practitioners should be aware that portion sizes of ultra-processed foods have not decreased significantly, which may impact dietary recommendations.

Reduced fat-free mass (FFM) is not the sole explanation for the lower energy expenditure seen in patients with PWS.

Practitioners should consider multiple factors affecting energy expenditure in PWS patients.

The safety of retatrutide needs to be determined in larger and longer trials.

Practitioners should be aware that more extensive safety data is needed before fully endorsing retatrutide.